Intellia Therapeutics (NTLA) Upgraded to C- by TheStreet
NTLA has been the subject of a number of other research reports. Oppenheimer restated a hold rating on shares of Intellia Therapeutics in a research report on Tuesday, December 12th. BidaskClub upgraded Intellia Therapeutics from a sell rating to a hold rating in a research report on Friday, December 29th. JMP Securities started coverage on Intellia Therapeutics in a research report on Thursday, March 8th. They issued an outperform rating for the company. Barclays raised their price target on Intellia Therapeutics from $33.00 to $46.00 and gave the company an overweight rating in a research report on Wednesday, March 7th. Finally, Wedbush restated an outperform rating and issued a $36.00 price target on shares of Intellia Therapeutics in a research report on Thursday, March 15th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $34.83.
Intellia Therapeutics stock opened at $23.77 on Monday. Intellia Therapeutics has a 52-week low of $11.15 and a 52-week high of $35.99. The firm has a market capitalization of $996.53, a price-to-earnings ratio of -12.78 and a beta of 2.42.
In related news, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of Intellia Therapeutics stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $26.78, for a total transaction of $14,746,273.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 12.80% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. MetLife Investment Advisors LLC purchased a new stake in Intellia Therapeutics during the 4th quarter worth about $146,000. SG Americas Securities LLC increased its position in Intellia Therapeutics by 61.3% during the 3rd quarter. SG Americas Securities LLC now owns 10,169 shares of the company’s stock worth $253,000 after purchasing an additional 3,863 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in Intellia Therapeutics during the 4th quarter worth about $230,000. The Manufacturers Life Insurance Company increased its position in Intellia Therapeutics by 451.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,224 shares of the company’s stock worth $212,000 after purchasing an additional 10,825 shares in the last quarter. Finally, New York State Common Retirement Fund increased its position in Intellia Therapeutics by 109.7% during the 2nd quarter. New York State Common Retirement Fund now owns 15,100 shares of the company’s stock worth $242,000 after purchasing an additional 7,899 shares in the last quarter. Hedge funds and other institutional investors own 67.02% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.